Having a little fun connecting the dots. I can ce
Post# of 72440
Posted On: 02/04/2016 8:34:09 PM
Having a little fun connecting the dots. I can certainly see why Cellceutix is gunning for ulcerative proctitis especially if B-OM proves the concept.
"Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug markets will double over the next decade, increasing to $3.7 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan."
http://www.fiercebiotech.com/press-releases/u...asing-37-b
Brilacidin is a "...synthetic small-molecules modeled after host defense peptides (HDP)."
"Host defense peptides secreted by colonocytes and Palneth cells play a key role in innate host defenses in the gut."
"A successful trial opens up a pathway for multiple GI diseases, which may be a far larger market for Cellceutix then even the anti-infective market for Brilacidin."
"Ulcerative proctitis is a mild form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. In this form of colitis, the inflammation begins at the rectum, and spreads no more than about 20cm into the colon. About 25-30% of people diagnosed with ulcerative colitis actually have this form of the disease.
The cause of ulcerative proctitis is undetermined, but there is considerable research evidence to suggest that interactions between environmental factors, intestinal flora, immune dysregulation, and genetic predisposition are responsible. It is unclear why the inflammation is limited to the rectum. There is a slightly increased risk for those who have a family member with the condition.
Although there is a range of treatments to help ease symptoms and induce remission, there is no cure. A diagnosis of ulcerative proctitis can occur at any point throughout life, with a high occurrence in young children and then again around 40-50 years of age. Progression of this disease to ulcerative colitis, extending farther up the bowel to involve the sigmoid colon, occurs in about 30-50% of patients with ulcerative proctitis."
http://www.badgut.org/information-centre/a-z-...proctitis/
"Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug markets will double over the next decade, increasing to $3.7 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan."
http://www.fiercebiotech.com/press-releases/u...asing-37-b
Brilacidin is a "...synthetic small-molecules modeled after host defense peptides (HDP)."
"Host defense peptides secreted by colonocytes and Palneth cells play a key role in innate host defenses in the gut."
"A successful trial opens up a pathway for multiple GI diseases, which may be a far larger market for Cellceutix then even the anti-infective market for Brilacidin."
"Ulcerative proctitis is a mild form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. In this form of colitis, the inflammation begins at the rectum, and spreads no more than about 20cm into the colon. About 25-30% of people diagnosed with ulcerative colitis actually have this form of the disease.
The cause of ulcerative proctitis is undetermined, but there is considerable research evidence to suggest that interactions between environmental factors, intestinal flora, immune dysregulation, and genetic predisposition are responsible. It is unclear why the inflammation is limited to the rectum. There is a slightly increased risk for those who have a family member with the condition.
Although there is a range of treatments to help ease symptoms and induce remission, there is no cure. A diagnosis of ulcerative proctitis can occur at any point throughout life, with a high occurrence in young children and then again around 40-50 years of age. Progression of this disease to ulcerative colitis, extending farther up the bowel to involve the sigmoid colon, occurs in about 30-50% of patients with ulcerative proctitis."
http://www.badgut.org/information-centre/a-z-...proctitis/
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼